TMS slows Alzheimer's disease in yearlong trial

A groundbreaking year-long clinical trial has shown promising results for slowing the progression of Alzheimer’s disease through non-invasive brain stimulation. Conducted by Cognito Therapeutics, the study utilized a wearable device, GammaSense, which delivers synchronized light and sound therapy at specific gamma frequencies to stimulate brain activity. Participants experienced a significant reduction in the rate of brain atrophy compared to historical data from untreated Alzheimer’s patients.

Over six months, the device appeared to enhance the brain’s immune response by activating microglia, cells responsible for clearing harmful proteins linked to neurodegeneration. Results demonstrated a 61% reduction in brain atrophy and improved cognitive and functional outcomes. These findings offer hope for a non-pharmacological approach to Alzheimer’s treatment, particularly since the therapy was well-tolerated and safe. The company plans to further validate its efficacy in upcoming pivotal trials.

This novel therapy could revolutionize Alzheimer’s care, potentially serving as a standalone or complementary treatment.

Read the full story here.